

MAILBOX NON-FINAL RESPONSES

Attorney Docket No. 24871

8. (Original) A pharmaceutical composition for use as an analgesic comprising a substantially non-toxic fraction according to claim 1 and a pharmaceutically acceptable carrier or excipient.
9. (Original) A pharmaceutical composition according to claim 8 for topical administration.
10. (Original) A pharmaceutical composition according to claim 8 for parenteral administration.
11. (Original) A pharmaceutical composition according to claim 8 for the treatment of pain.
12. (Original) A method for the relief of pain of a subject comprising administering to said subject a substantially non-toxic fraction according to claim 1.
13. (Original) A method according to claim 12 wherein said fraction is topically administered.
14. (Currently Amended) A method for isolating a substantially non-toxic fraction from snake venom, wherein said fraction has an analgesic effect, comprising applying whole venom to an ion exchange column and eluting the fraction with an aqueous buffer, wherein said snake is selected from the group of snake families consisting of Atractaspidae, Elapidae, Crotalidae, ~~Crotelidae~~, Hydrophidae and Viperidae, with the exception of Vipera Xanthina.
15. (Original) A method of claim 14, wherein said column is a Mono Q ion-exchange column.
16. (Original) A method of claim 15 wherein said column is eluted with a TRIS-HCl buffer or with an ammonium acetate buffer.
17. (Original) A method according to claim 16 wherein the concentration of said buffer is 20mM and the pH is in the range of 6.8-7.5.
18. (Original) A method according to claim 17 wherein said fraction elutes at 12-28 minutes.

REMARKS

THE PENDING CLAIMS

Claims 1-18 were pending in this application, claims 1, 3 and 14 have been amended, claims 6-7 canceled, and claim 4 withdrawn from consideration (possible as being directed to a non-elected